Advertisement
Higher complete reperfusion rate seen with tenecteplase vs. alteplase in single-center study of stroke with LVO
$2M NIH grant will help see if dual-action agent lengthens treatment window
Improved 90-day mRS scores mark first demonstration of clinical benefit with a mobile unit
Successful outcome with no harm to mother or newborn
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
And introducing telemedicine may bolster cost-effectiveness
Advertisement
Advertisement